August 2025 | Endo Lab & Medical Systems – Clinical Lab Newsletter
Innovation, Regulation, and Strategic Trends in Molecular Testing & Remnant Sample Research
1. Multi-Omic Testing: Integrating Genomics, Proteomics, and Phenotypic Data
Multi-omic platforms are transforming how clinical labs and research centers approach complex disease diagnostics by integrating data layers across:
Genomics (DNA/NGS)
Transcriptomics (RNA expression)
Proteomics (protein biomarkers)
Metabolomics (metabolic signatures)
Phenotypic data (EHR, clinical outcomes, digital pathology)
Notable developments:
NIH’s All of Us Research Program has released over 1 million multi-omic records (including DNA, RNA, EHRs, and wearable data) to support population-scale disease risk modeling.
OncoMX and Tempus are scaling multi-omic assays in oncology, enabling predictive models for treatment response.
AI tools are now being used to correlate multi-omic markers with rare phenotypes in neurodegenerative, autoimmune, and oncologic diseases.
Clinical remnant samples (e.g., blood, plasma, FFPE) are increasingly used as inputs for multi-omic profiling — eliminating the need for fresh draws or biobank recruitment.
For labs and partners with access to high-quality biospecimens, multi-omic-enabled diagnostics are a growing opportunity in both translational research and companion diagnostics development. Contact EndoLabs for ways to minimize the costs of this type of testing. Info@endogroupllc.com
2. Waters and Becton Dickinson Merge to Accelerate Multiplex Diagnostics & Bioseparations Waters Corporation is set to merge its Bioseparations and Bioanalytical Characterization business with Becton, Dickinson & Company’s Biosciences & Diagnostic Solutions division in a reverse Morris Trust transaction, valued at approximately $17.5 billion. This strategic consolidation is poised to:
Double the combined entity’s addressable market to $40 billion, enhancing scale and reach.
Strengthen capabilities in bioseparations, bioanalytical characterization, and advanced multiplex diagnostic assays—domains essential for molecular testing, clinical proteomics, and multi‑omic assay workflows.
Deliver $345 million in annual cost synergies by 2030, boosting operational efficiencies.
Be completed in Q1 2026, with the combined entity projected to realize $6.5 billion in revenue for 2025
3. Clinical Remnants: From Discard to Diagnostic Discovery
Remnant biospecimens (e.g., blood, serum, swabs) are becoming central to assay development, AI modeling, and molecular validation.
✔ IRB-approved programs at Boston Univ LABS Core, Bloodworks, and others
✔ HIPAA-compliant pipelines with EMR linkage
✔ Key for rare disease, oncology, and early-phase diagnostics
💡 If your lab is interested in monetization of remnant samples or R&D collaboration, let’s connect: David.curley@endogroupllc.com
Upcoming Events
📍 AMP Molecular Summit – Oct 28–Nov 1, Houston
📍 ECP 2025 – Sept 6–10, Florence
📍 WHX Labs – Sept 2–4, Cape Town
📍 Clinical Lab 2.0 – Mar 2026, Chicago
Let us know if you’re planning to attend any shows this year. We would love to meet you in person.
Let’s Collaborate
Endo is actively partnering with labs to:
Procure remnant biospecimens
Validate molecular assays under new regulations
Expand multi-omics and phenotypic data research
👉 Reply to this email or contact us to discuss your lab’s sample volume, capabilities, or research goals.
Fun Fact:
Over 90% of clinical research assays used to validate new molecular tests in the U.S. begin with remnant samples from routine patient testing — meaning that yesterday’s "waste" is often the foundation of tomorrow’s breakthrough diagnostic!
Have questions, ideas, or want to feature your lab in next month’s edition?
Reply to this email or contact us at info@endolabsystems.com.
Stay smart, stay compliant.
